{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"6"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. A TEAE was defined as any adverse event either reported for the first time or the worsening of a pre-existing event after the first dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated. Grade 5: death due to AE.","groups":[{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 70 milligrams (mg) every 2 weeks (Q2W) beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as intravenous (IV) infusions.","id":"OG000","title":"Phase 1, Dose Escalation: INCAGN01949 70 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 200 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG001","title":"Phase 1, Dose Escalation: INCAGN01949 200 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 350 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG002","title":"Phase 1, Dose Escalation: INCAGN01949 350 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 700 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG003","title":"Phase 1, Dose Escalation: INCAGN01949 700 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 70 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kilogram (kg) every 6 weeks (Q6W) beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG004","title":"Phase 1, Dose Escalation: INCAGN01949 70 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 200 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kg Q6W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG005","title":"Phase 1, Dose Escalation: INCAGN01949 200 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 350 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kg Q6W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG006","title":"Phase 1, Dose Escalation: INCAGN01949 350 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 700 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kg Q6W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG007","title":"Phase 1, Dose Escalation: INCAGN01949 700 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 70 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 3 Day 1, administered as IV infusions.","id":"OG008","title":"Phase 1, Safety Expansion: INCAGN01949 70 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 200 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 3 Day 1, administered as IV infusions.","id":"OG009","title":"Phase 1, Safety Expansion: INCAGN01949 200 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 350 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 3 Day 1, administered as IV infusions.","id":"OG010","title":"Phase 1, Safety Expansion: INCAGN01949 350 mg + Nivolumab 240 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"FAS","reportingStatus":"POSTED","timeFrame":"up to 17.4 months","title":"Phase 1: Number of Participants With a Grade 3 or Higher TEAE","type":"PRIMARY","unitOfMeasure":"Participants"}